Skip to main content

Table 2 Treatment-related adverse events by pyrotinib combined with apatinib

From: Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)

Event

Patients (N = 33)

Any grade, n (%)

Grade 3, n (%)

Diarrhea

30 (90.9)

1 (3.0)

Hypertension

24 (72.7)

3 (9.1)

Anorexia

18 (54.5)

0 (0.0)

Nausea

17 (51.5)

0 (0.0)

Oral mucositis

15 (45.5)

0 (0.0)

Erythra

13 (39.4)

0 (0.0)

Vomiting

10 (30.3)

0 (0.0)

Hand-foot syndrome

9 (27.3)

0 (0.0)

Abdominal pain

7 (21.2)

0 (0.0)

Blood creatinine increased

6 (18.2)

0 (0.0)

Thrombocytopenia

4 (12.1)

0 (0.0)

Anemia

3 (9.1)

0 (0.0)

ALT increased

3 (9.1)

0 (0.0)

AST increased

3 (9.1)

0 (0.0)

Paronychia

3 (9.1)

0 (0.0)

Leukopenia

2 (6.1)

0 (0.0)

Proteinuria

2 (6.1)

0 (0.0)

  1. ALT Alanine aminotransferase, AST Aspartate aminotransferase